New chemoimmunotherapy: courtesy of a more flexible Food and Drug Administration.
Greenspan
E M
EM
Department of Medicine (Oncology), Mount Sinai School of Medicine, New York, New York, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017277:Drug Approval; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007978:Levamisole / Q000627:therapeutic use; D009163:Mycobacterium bovis / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D007978:Levamisole